Rani Therapeutics Holdings, (id:6601 RANI)
2.08 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 9:00:15 PM)
Exchange closed, opens in 1 day 12 hours
About Rani Therapeutics Holdings,
Market Capitalization 121.78M
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
| Headquarters (address) |
2051 Ringwood Avenue San Jose 95131 CA United States |
| Phone | 408 457 3700 |
| Website | https://www.ranitherapeutics.com |
| Employees | 140 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | RANI |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.90 - 8.75 |
| Market Capitalization | 121.78M |
| P/E trailing | -1.56 |
| P/E forward | -2.06 |
| Price/Book | 4.21 |
| Beta | 0.114 |
| EPS | -1.05 |
| EPS United States (ID:6, base:3403) | 24.22 |